Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hormonal therapies

ADT for prostate cancer: true love or heartbreak?

Nature Reviews Clinical Oncology volume 7, pages 130–132 (2010)Cite this article

Subjects

The addition of hormonal therapy to radiation therapy improves survival in men with unfavorable risk prostate cancer. Yet, men with prostate cancer have higher rates of non-cancer death than the general population and most will die from causes other than their index malignancy. Co-morbid cardiovascular disease is strongly associated with cause of death and this raises the possibility that prostate cancer or its treatment increases cardiovascular disease risk and possibly mortality.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).

    Article  CAS  PubMed  Google Scholar 

  2. Efstathiou, J. A. et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J. Clin. Oncol. 27, 92–99 (2009).

    Article  PubMed  Google Scholar 

  3. Efstathiou, J. A. et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02. Eur. Urol. 54, 816–823 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Roach, M. 3rd et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585–91 (2008).

    Article  PubMed  Google Scholar 

  5. D'Amico, A. V. et al. The influence of androgen suppression therapy for prostate cancer on the timing of a fatal myocardial infarction. J. Clin. Oncol. 25, 2420–2425 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Alibhai, S. M. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 27, 3452–3458 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Beyer, D. C., McKeough, T. & Thomas, T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 61, 1299–1305 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Nanda, A., Chen, M. H., Braccioforte, M. H., Moran, B. J. & D'Amico, A. V. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 3 02, 866–873 (2009).

    Article  Google Scholar 

  9. Barry, M. J., Delorenzo, M. A., Walker-Corkery, E. S., Lucas, F. L. & Wennberg, D. C. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 98, 973–978 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  10. McKoy, J. M. et al. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J. Clin. Oncol. 23, 8894–8905 (2005).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, 02114, MA, USA

    Jason A. Efstathiou, William U. Shipley & Anthony L. Zietman

  2. Division of Hematology and Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, 02114, MA, USA

    Matthew R. Smith

Authors
  1. Jason A. Efstathiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William U. Shipley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony L. Zietman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew R. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason A. Efstathiou.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Efstathiou, J., Shipley, W., Zietman, A. et al. ADT for prostate cancer: true love or heartbreak?. Nat Rev Clin Oncol 7, 130–132 (2010). https://doi.org/10.1038/nrclinonc.2010.12

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.12

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing